Several clinical (e.g., patient age at diagnosis and Karnofsky Performance Status (KPS)) and therapeutic (extent of surgery, radiation therapy and chemotherapy) factors, as well as specific tumour characteristics (e.g., volume and location) and histopathological and genetic markers (Ki67, isocitrate dehydrogenase 1—IDH1—mutation status and O6-methylguanin-DNA-methyltransferase—MGMT—promoter methylation status) have been studied as potential prognostic markers of survival with variable degrees of sensitivity and specificity [12]. This evidence concerns the gene MGMT and neoplasm.